Tissue engineering methods and compositions
Inventors
Guilak, Farshid • Estes, Bradley T. • Moutos, Franklin Thomas
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9649409-B2
Publication Date
2017-05-16
Expiration Date
Abstract
Cells are employed in conjunction with unique biologically-compatible scaffold structures to generate differentiated tissues and structures, both in vitro and in vivo. The presently disclosed subject matter further relates to methods of forming and using improved tissue engineered scaffolds that can be used as substrates to facilitate the growth and differentiation of cells.
Core Innovation
The invention relates to tissue engineering approaches that use adipose-derived stem cells (ADS/hADS) combined with biologically active differentiation factors to induce chondrogenic or cartilage-like phenotypes. The disclosure emphasizes differentiation induced by bone morphogenetic protein-6 (BMP-6) and relates the resulting chondrogenic phenotype to tissue pathology treatment.
A described problem in the background is the need for improved therapeutic approaches to treat tissue pathologies, including joint and articular cartilage damage, using engineered or induced chondrogenic outcomes. The invention addresses this by providing ADS/hADS-based differentiation toward cartilage-like characteristics using biologically active differentiation factors, particularly BMP-6.
The disclosure further describes concepts for joint resurfacing implants using biocompatible fiber scaffolds and composites, and the use of three-dimensional scaffolds and optional genetic modification in connection with ADS/hADS and differentiation factors. The engineered constructs are framed within tissue engineering systems that include differentiation detection and evaluation of cartilage-related biosynthetic and gene expression outputs.
Claims Coverage
Not explicitly described in patent.
Not explicitly described in patent.
Stated Advantages
Provides ADS/hADS-driven differentiation toward robust chondrogenic markers using BMP-6.
BMP-6 suppresses hypertrophic marker COL10A1 while promoting cartilage-related gene expression markers.
Supports cartilage-like phenotypes relevant to treating joint and articular cartilage tissue pathologies.
Documented Applications
Treatment of tissue pathologies, including joint and articular cartilage.
Joint resurfacing implant concepts using biocompatible fiber scaffolds and composites.
Interested in licensing this patent?